https://www.aditumbio.com/news/aditum-announces-kalexo-bio 2025-09-17 https://www.aditumbio.com/news/tempero-bio-secures-70-million-series-b-financing-to-advance-tmp-301-into-phase-2- 2025-03-24 https://www.aditumbio.com/news/aditum-bio-and-leads-biolabs-announce-the-formation-of-oblenio- 2025-03-24 https://www.aditumbio.com/news/via-nova-therapeutics-announces-fda-clearance-of-investigational-new-drug 2025-03-24 https://www.aditumbio.com/news/aditum-bio-announces-formation-of-celexor-bio 2025-03-24 https://www.aditumbio.com/news/lilly-completes-acquisition-of-versanis-bio 2025-03-24 https://www.aditumbio.com/news/aditum-bio-announces-formation-of-vitalli-bio 2023-04-28 https://www.aditumbio.com/news/aditum-bio-launches-second-startup 2023-08-28 https://www.aditumbio.com/news/joe-jiminez-and-mark-fishman-have-133m-for-startups 2023-08-28 https://www.aditumbio.com/news/joe-jiminez-and-mark-fishman-unveil-aditum-bio 2023-08-28 https://www.aditumbio.com/news/sosei-allies-with-ex-novartis-team-developing-neurological-drug-pipeline 2023-08-28 https://www.aditumbio.com/news/aditum-bio-forms-second-company 2023-01-30 https://www.aditumbio.com/news/aditum-bio-launches-tempero-bio 2023-08-28 https://www.aditumbio.com/news/aditum-bio-announces-anteris-bio 2023-01-30 https://www.aditumbio.com/news/aditum-bio-announces-formation-of-ancora-bio 2023-01-30 https://www.aditumbio.com/news/versanis-bio-announces-70m-series-a-financing 2023-01-30 https://www.aditumbio.com/news/via-nova-announces-20m-series-a-financing 2023-01-30 https://www.aditumbio.com/news/stephen-kanes-appointed-ceo-of-ancora-bio 2023-01-30 https://www.aditumbio.com/news/aditum-bio-announces-formation-of-motric-bio 2023-01-30 https://www.aditumbio.com/news/embark-neuro-announces-phase-2-trial-of-anc501 2023-01-30 https://www.aditumbio.com/news/tempero-bio-announces-fda-clearance 2023-01-30